

Media Contact: Caroline Grossman • 781.771.5579 • cgrossman@magellanbio.com

Magellan Biosciences Sells its Life Sciences Tools Business to Dionex Company to focus on clinical-diagnostic systems and tests designed to help doctors make faster, more-informed treatment decisions

CHELMSFORD, Massachusetts (September 22, 2009) – Magellan Biosciences, Inc. (Magellan), an emerging leader in clinical diagnostics, has sold its ESA Life Sciences Tools (LST) business to Sunnyvale, California-based Dionex, Inc. (NASDAQ: DNEX). The sale includes all of ESA's HPLC-related products, HPLC clinical assays, the ESA Laboratories services and assets, as well as ESA's headquarters in Chelmsford, Massachusetts. Financial terms of the transaction were not disclosed.

"This sale enables Magellan to concentrate on our clinical-diagnostic customers. We can now apply all of our resources to developing and supporting innovation in diagnostic products that give clinicians the answers they need to make more-informed treatment decisions for superior, outcomes-based care," said Magellan President and Chief Executive Officer, Robert J. Rosenthal, Ph.D. "Stay tuned. Over the next several months we will be highlighting the new diagnostics-focused Magellan. In the meantime, customers can continue to count on the Magellan brands and people they've come to know: LeadCare® for blood-lead-testing systems, Dynex® for automated ELISA processing systems, and TREK for microbiology."

LeadCare – Because traditional prescription-based and send-out practices have missed those children most at-risk for lead poisoning, policy-makers at the federal, state, and local level are taking action to encourage the use of the **LeadCare II** system to ensure that children receive mandated testing. For example, New York State Medicaid just began reimbursing doctors and health clinics for LeadCare II tests. As a CLIA-waived test, the LeadCare II system removes all the complications formerly associated with blood-lead testing – waiting days for lab results, spending precious staff time and resources trying to contact patients for critical follow-up care, or tracking down results for record-keeping, reporting, or compliance purposes. Visit www.WaivedLeadCare.com to learn more. For important lead-poisoning prevention resources, links to consumer product recall information, and tips for keeping children safe, visit www.LeadPoisonInfo.com.

Dynex – The **DS2**® two-plate and **DSX**® four-plate ELISA processing systems are designed for efficiency and reliability with the 'expert' inside. They perform the most-sophisticated analyses, but are easy to use for operators with varying levels of education and experience. The DSX and DS2 are open systems with full walk-away automation and precise liquid-handling capabilities. They execute the entire complement of analytical steps required for virtually any ELISA immunoassay: adding samples and reagents, washing, incubation, and detection, delivering all you need to ensure the rigorous, repeatable analyses required in critical applications – from immunology to infectious disease, hormone, allergy, blood-chemistry, and drugs-of-abuse testing. To see a video of the DS2 at work, visit www.dynextechnologies.com.

TREK – The award-winning **VersaTREK**® automated microbial-detection system performs four tests on one automated platform: culture for blood, sterile body fluids, and mycobacteria detection, as well as Mycobacterium tuberculosis (TB) susceptibility testing. TREK's signature **Sensititre**® product line for susceptibility and identification testing enables labs to test – on a single cost-effective, LIS-compatible system – more FDA-cleared antimicrobial drugs than on any other automated platform against the widest range of non-fastidious and fastidious bacteria and yeasts. This saves microbiology labs from having to use multiple off-line test procedures to obtain accurate susceptibility data. TREK's platform is the system-of-choice for global surveillance initiatives, including NARMS (National Antimicrobial Resistance Monitoring System). For more information on TREK products, visit www.trekds.com.

About Magellan (www.magellanbio.com)

An emerging leader in clinical-diagnostic markets for near-patient testing, hospital-based labs, and microbiology, Magellan serves customers worldwide with rapid point-of-care analyzers and consumables; blood culture, antimicrobial-susceptibility tests, systems, and reagents; as well as automated ELISA processing systems, microplate instrumentation, and associated consumables. We design all our products to deliver better, faster, more-reliable diagnostic results to help doctors make more-informed treatment decisions and improve health outcomes. Magellan brands include LeadCare, Dynex, and TREK.